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Transmissible spongiform encephalopathies (TSE) 
belong to the group of neurodegenerative disorders, 
which are characterised by the conversion of the cellular 
prion protein (PrPC) to the disease-associated misfolded 
form PrPScrapie (PrPSc). This group includes 
Creutzfeldt-Jakob disease (CJD), the most common 
form of prion disease in humans. CJD can be sporadic, 
genetic and acquired. All prion diseases are not curable 
with a rapid disease progression (survival time usually 6 
months after disease onset). 
 
The PrP gene (PRNP) encodes at codon 129 either the 
amino acid methionine (M) or valine (V). In the 
Caucasian population about 40% is homozygous for 
methionine, about 50% methionine/valine heterozygous,  
 
and about 10% homozygous for valine. The PRNP 
codon 129 polymorphism influences the conformational 
structure of the cellular PrP (PrPC) [1] and it may 
influence the disease course, symptoms at onset, type of 
the pathological changes such as the PrPSc deposition 
pattern and the sensitivity of diagnostic tests [2-5].  
 
Although the diagnostics of sCJD has been improved 
markedly during the recent years, autopsies are still 
necessary for a confirmed diagnosis. All biomarkers 
which are currently available, such as 14-3-3, total tau 
(tau), S-100 calcium-binding protein B (S-100B), alpha-
synuclein or neuron specific enolase (NSE) and the 
recently established in vitro amplification assays real 
time quaking induced conversion (RT-QuIC), have a 
relative high accuracy but their sensitivities depending 
from the PRNP codon 129 MV genotype are ranging 






















level  of  an  enzyme, mitochondrial malate  dehydrogenase  1  (MDH1),  in  sporadic  Creutzfeldt‐Jakob  disease
(sCJD) patients. Here, we could demonstrate the expression of MDH1 in neurons as well as in the neuropil. Its
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between 80-90%, which may result in false negative 
diagnoses [6-15]. 
 
In this context, a previous high-throughput two-
dimensional proteomic approach on sCJD brain 
homogenates and CSF in our group indicated a 
regulation of mitochondrial malate dehydrogenase 1 
(MDH1), an enzyme that reversibly catalyses the 
oxidation of malate to  oxaloacetate (part of 
many metabolic pathways, including the citric acid cycle) 
[16],  in  sCJD patients compared to controls [17, 18].   
 
These findings prompted us to measure the 
concentration of MDH1 in brain tissue and CSF of 
sCJD patients (different geno- and subtypes) in 
comparison to control cases. Moreover, we analysed the 
diagnostic accuracy of MDH1 alone and in combination 
with surrogate biomarkers. To estimate the association 
of MDH1 level with other neurodegenerative marker 
proteins, we additionally performed a correlation 
analysis between MDH1 and tau, p-tau, 14-3-3, S-100B, 




Analysis of MDH1 expression and localization 
in sCJD brain tissue 
 
The level of MDH1 in the frontal cortex region of sCJD 



























signal was quantified by using the software Image J 
software.  Interestingly, we found levels of MDH1 
reduced in brain tissue of sCJD patients compared to 
control brains (from patients without prion disease) (Fig. 
1A).  
 
Immunohistochemical staining of cytosolic MDH1 was 
performed in the frontal cortex region of sCJD (MM1) 
patients in comparison to non-prion disease controls. 
We observed MDH1 expressed in neurons as well as in 
the neuropil. The intensity of MDH1 staining was lower 
in sCJD cases than in controls, which was in agreement 
with the western blot observations (Fig. 1B).   
 
Determination of CSF-MDH1 levels in sCJD patients 
 
At first, we investigated the levels of MDH1 by ELISA 
(indicated as million units per mL (mU/mL)) in CSF of 
sCJD patients in comparison to control cases without 
prion disease. The obtained data revealed a statistically 
significant difference between sCJD and controls 
(p<0.001) indicating that CSF-MDH1 is specifically 
increased in sCJD patients (Fig. 2A). The 
discrimination accuracy between sCJD and controls was 
0.91 AUC (p<0.0001). Setting a cut off at 1530 mU/mL 
(defined by Youden index), the test exhibited a 
specificity of 85.0% and a sensitivity of 82.9% (Fig. 2B, 
Table 1). When we stratified our sCJD cohort according 
to three PRNP codon 129 genotypes (MM, MV, VV) as 































comparison  between  two  groups we  used  the Wilcoxon Mann Whitney  test  as  appropriate.  A  p‐value  <  0.001  is  considered  as
extremely significant (***), < 0.01 as very significant (**), < 0.05 as significant (*) and ≥ 0.05 as not significant (ns). 
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effect of the PRNP genotype or the type of PrPSc on the 
MDH1 level (Fig. 2C, D).  
 
Analysis of diagnostic accuracy of MDH1 in 
comparison to 14-3-3 and tau as well as in 
combination 
 
At first, we determined the diagnostic values of both 
neurodegenerative markers, 14-3-3 and tau, in 
comparison to MDH1. Both markers revealed a slightly 
higher sensitivity and a lower specificity than MDH1 
(Table 1). As reported before, a combination of 
different biomarker proteins may improve the 
diagnostic value and reliability of biomarker detection 
[11, 27, 28]. Therefore, we explored if the combination 
of MDH1/14-3-3, MDH1/tau and 14-3-3/tau may 
increase the diagnostic accuracy. Interestingly, the 
combination of MDH1 with tau revealed the highest 





































sensitivity of 97.5% and a specificity of 95.6% 
compared to others combinations (Table 1). 
 
Correlation between MDH1 and other 
neurodegenerative markers 
 
To examine a potential association between MDH1 and 
other already known neurodegenerative biomarker 
proteins, we initiated a correlation study. All marker 
concentrations were determined in the same patients. 
Interestingly, we observed in sCJD patients a positive 
relationship between MDH1 concentration and tau, 14-
3-3 and NSE levels (Fig. 3A, C, D) while a negative 
correlation was found between MDH1 concentration 
and Aβ1-40 level (Fig. 3F). In contrast, no correlation 
was observed between MDH1 concentration and p-tau-, 
S-100B, Aβ1-42 level and Aβ1-42/1-40 ratio (Fig.3B, 




































Figure 2. Determination of MDH1 levels in CSF of sCJD patients. MDH1 was quantified by ELISA in CSF of sCJD and control
patients.  (A) Patients with sCJD  (n=82) exhibited a significantly  increased  level of MDH1 compared  to controls  (n=60).  (B) ROC
curve analysis was performed for the discrimination between sCJD patients and controls. (C‐D) MDH1 analysis of different PRNP
































In the prion disease field, the need for an improved 
diagnostic accuracy requires the identification of novel 
biomarkers. Even though already known biomarkers 
such as 14-3-3 and tau or the detection of PrPSc by RT-
QuIC has exhibited a high diagnostic accuracy to 
discriminate CJD from control cases [11, 15, 28], there 
is no marker available which shows a sensitivity close 
to 100%. Most markers are described with a sensitivity 
varying between 80-90% [9, 11, 15, 28, 29]. 
 
A previously conducted two-dimensional proteomic 
study on CJD brain homogenates and CSF indicated a 
specific regulation of MDH1 in sCJD patients compared 
to controls [17, 18].  
 
We could confirm the decrease of MDH1 in the frontal 
cortex brain region of sCJD patients by western blotting 
and by immunohistochemical analysis which further 
revealed the expression of MDH1 in neurons as well as 
in the neuropil. Since MDH1 is involved in the energy 
metabolism our observations fits to previous data 
indicating that the energetic metabolism is altered in 
sCJD [30].  
 
This very interesting finding encouraged us to study the 
MDH1 level in CSF of sCJD patients, in comparison to 





























Our objectives were to evaluate the potential of MDH1 
to discriminate sCJD patients from controls as well as to 
analyse the influence of the PRNP-codon 129 MV 
genotype and the PrPSc type on the CSF level of MDH1. 
Interestingly, we observed an inverse relationship 
between MDH1 level in brain and CSF. An explanation 
may be that cytosolic neuronal MDH1 is released into 
the extracellular space as a consequence of neuronal 
damage. Therefore, lower levels are detectable in post-
mortem sCJD brains, where massive neuronal damage 
has already occurred. As a consequence of neuronal 
damage, MDH1 can be filtered to the CSF where 
elevated levels can be detected. This is in agreement 
with similar brain-CSF correlations detected for other 
sCJD surrogate markers such as 14-3-3 and tau [31]. 
 
 For diagnostic discrimination, the higher MDH1 level in 
CSF of sCJD patients (compared to controls) revealed a 
specificity of 85.0% and a sensitivity of 82.9%. Com-
pared to that, 14-3-3 and tau exhibited sensitivity values 
of 85.4% and 89.0%, which is in line with others [9, 11, 
28, 29] and slightly higher than the sensitivity of MDH1. 
 
However, when we examined the sensitivities of 
different biomarkers in combination, we observed that 
the MDH1/tau combination revealed the best diagnostic 
accuracy with a sensitivity  of 97.5%  and a specificity 
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already reported that a combined determination of 14-3-3 
and tau, S-100B, or NSE increases the sensitivity to over 
93% for sCJD [28], which highlights the importance of a 
combinative biomarker analysis. Variations among 
different studies may be explained by composition of the 
patient cohort different test systems, or by demographical 
differences.      
                                                                                                                                                                                                      
When we analysed the impact of the PRNP codon 129 
MV polymorphism and the PrPSc type on MDH1 levels, 
both influence clinical and pathological phenotype of 












































did not depend on either of these factors. Other 
diagnostic biomarker or assays, such as 14-3-3 or RT-
QuIC also failed to distinguish between different sCJD 
genotypes or PrPSc type 1 and 2  [32, 33]. In contrast, 
tau can be used to assess the PrPSc type in sCJD cases 
but not PRNP codon 129 genotype [34].  
 
Correlation studies of MDH1 levels with several
neurodegenerative marker proteins such as tau, 14-3-3 
and NSE revealed significant correlations between the 
MDH1 and these marker proteins, which indicate a 













































Figure 3. Correlation between MDH1 and neurodegenerative biomarker proteins. In sCJD patients, a positive correlation was
obtained between MDH1 level and the tau (r=0.27; p=0.029*; n=72), 14‐3‐3 (r=0.60; p=0.03*; n=13), NSE (r=0.39; P=0.01*; n=40) levels
(A, C, D). MDH1 levels concentrations correlated negatively to Aβ1‐40 (r=‐0.47, p=0.04*, n=20) (F). No correlation was detected between
MDH1 and p‐tau  (r=0.17, p=0.31, n=38), S‐100B  (r=0.26; p=0.08; n=43), Aβ1−42  (r=‐0.33, p=0.09, n=26)  levels and  the Aβ1‐42/Aβ1‐40
ratio  (r=0.08, p=0.7, n=20)  (B, E, G, H). All correlation studies were computed by using  the non‐parametric Spearman correlation  test
(two‐tailed) in a confidence interval of 95%. A p‐value < 0.001 is considered as extremely significant (***), < 0.01 as very significant (**), <
0.05 as significant (*) and ≥ 0.05 as not significant (ns). 
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brains of sCJD patients.  It can be speculated whether 
neuronal MDH1 also reflects the extent of neuronal 
damage in the brain tissue.    
 
For a further evaluation of MDH1 as an additional 
marker in sCJD diagnosis as well as in combination 
with tau, present findings must be validated in a larger 
patient cohort and the reproducibility of the test needs 
to be proven by ring trial studies. Moreover, a potential 
association of MDH1 with the disease stage or the 
duration of the disease needs to be investigated further. 
 
In conclusion, the present study has suggested CSF-
MDH1 as a potential novel diagnostic biomarker in 
sCJD, in particular the combination of MDH1 and tau 
improved the sensitivity of both markers markedly.  
 




The cohort of patients in this study consisted of 82 
sCJD (44 male, 38 female), (26xMM, 26xMV and 
30xVV) aged 53-83 years; mean age 64.9 ± 8.5 years. 
 
Thirty five patients were classified as definite cases by 
neuropathological examinations, the rest as probable 
CJD cases according to diagnostic consensus criteria 
[19-22]. 
 
Age and gender matched control cases (n=60) are 
patients with an either clinically or pathologically 
defined alternative diagnosis, such as psychiatric 
disorders, dizziness, headache, vasculitis, encephalitis, 
viral meningitis, neuroborreliosis, Parkinson’s disease, 
vascular dementia, Alzheimer’s disease and normal-
pressure hydrocephalus. 
 
 After collection,  CSF samples were centrifuged for 10 
min at 720 x g (Eppendorf model no. 5415C centrifuge) 
at room temperature (~22 °C), aliquoted in 1 mL portions 
and stored at -80°C. Blood-stained CSF samples were 
excluded from the study and we avoided thawing and 
refreezing the same samples more than 8 times. 
 
The analysis of the codon 129 genotype of PRNP was 
performed after isolation of genomic DNA from blood 
samples according to standard methods [23].  
 
Determination of human malate dehydrogenase 1 
 
CSF levels of human MDH1 were measured using a 
commercially available ELISA kit (Cusabio, Hubei, 
China). We followed the manufacturer’s instructions. 
Briefly, levels of MDH1 were measured in million units 
(mU) per mL. The detection range of the assay reaches 
from 9.38 mU/mL to 600 mU/mL. To be in this range, 
CSF samples were measured in a dilution of 1:100 
using the sample diluent buffer supplied in the kit. 
Colorimetric reaction was measured at 450 nm with a 
1420 Multilabel Counter Victor 2 (Wallac) (PerkinElmer, 
Massachusetts, USA).  
 
Determination of 14-3-3 protein gamma in CSF by 
ELISA  
 
The amount of 14-3-3 gamma protein in CSF was 
ascertained by using the CircuLex 14-3-3 Gamma 
ELISA Kit (BIOZOL Diagnostica Vertrieb GmbH, 
Eching, Germany) by following the manufacturer’s 
instructions and as described before [11].  Briefly, CSF 
samples were applied in a dilution of 1:5 in dilution 
buffer. The level of 14-3-3 gamma was measured in 
arbitrary units (AU) per mL (1 AU is almost equal to 1 
pg). For capturing, CSF samples were incubated for one 
hour at room temperature. After washing, 14-3-3 
gamma detection antibody and later horseradish 
peroxidase-conjugated anti-IgG were added and 
incubated for one hour at room temperature each. 
Colorimetric reaction was measured at 450 nm using a 
1420 Multilabel Counter Victor 2 Wallac) 
(PerkinElmer, Massachusetts, USA).  
 
Determination of Aβ1-40 and Aβ1-42 levels in CSF 
 
Levels of Aβ1-40 were measured by using the full-length 
Aβ1-40 high sensitive assay ELISA obtained from IBL 
(Hamburg, Germany) with a detection range between 
1.56-100 pg/mL. Levels of Aβ1-42 were ascertained by 
the use of an ELISA kit named INNOTEST®-
AMYLOID (1–42) (Innogenetics, Hannover, Germany) 
with a detection range between 125-2000 pg/mL. All 
ELISA measurements were performed according to the 
protocol of the manufacturer.  
 
Determination of tau and p-tau 181 levels in CSF 
 
CSF levels of tau were determined by using an ELISA 
kit from INNOTEST® hTAU Ag (Innogenetics) with a 
detection range between 50-2500 pg/mL (detection 
limit: 34 pg/mL). Concentration of phosphorylated tau 
at threonine-181 (p-tau) was measured by using an 
ELISA kit named INNOTEST®PHOSPHO-TAU (181 
P) (Inno-genetics) with a detection range between 15.6-
1000 pg/mL (detection limit: 3 pg/mL). 
 
Briefly, before antibody incubations, each sample (75 
µl) was diluted 1:1 in sample diluent. The colorimetric 
reaction was measured at 450 nm with a 1420 
Multilabel Counter Victor 2 (Wallac) (PerkinElmer). 
Each sample was measured in duplicate. For analysis 
we calculated the median. 
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SDS-PAGE and immunoblotting 
 
For Western blot analysis we followed a modified 
protocol as described previously [24, 25]. A monoclonal 
MDH1 antibody (Acris-Antibodies GmbH, Herford, 
Germany) was diluted 1:1000. As a secondary antibody 
we used a polyclonal horseradish peroxidase-conjugated 
antibody (Jackson Immuno Research, Leipzig, 
Germany).  
 
For denaturation samples were heated for 2 min at 
95°C, after 10 µL sample loading buffer (Bio-Rad 
Laboratories GmbH, Munich, Germany) had been 
added. Protein separation occurred by sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) (12% w/v polyacrylamide). Subsequently, 
proteins were transferred to polyvinylidene difluoride 
(PVDF) Hydrobond-P membranes (Amersham, 
Freiburg, Germany) using a semi-dry transblot cell. 
After blocking with 5% dried milk in PBS and 0.1% 
Tween-20 for 1 h at room temperature, samples were 
incubated with the primary antibody overnight at 4°C. 
Membranes were rinsed in PBS-Tween and incubated 
with the corresponding horseradish peroxidase-
conjugated secondary antibody (Jackson Immuno 
Research, Leipzig, Germany) (diluted 1:10000). Protein 
bands were visualized after immersion of the 
membranes in enhanced chemiluminescence (ECL) 
detection system solution using Chemicon system (Bio-
Rad Laboratories GmbH). The western blot bands 
obtained from 8 control- and 8 sCJD cases (frontal 
cortex region 8) were quantified by densitometry using 
Image J software. MDH1 levels were normalized with 
those obtained from the loading control protein 




Brain samples (frontal cortex region 8) from sCJD 
MM1 patients (n= 5) and aged matched controls (n= 4) 
were treated with formic acid and were embedded in 
paraffin. Sections, 4 microns thick, were treated with 
citrate buffer (20 min) to enhance antigenicity. 
Endogenous peroxidases were blocked  with 10% 
methanol and 1% H2O2 (15 min) followed by 3% 
normal horse serum and then incubated at 4ºC overnight 
with the primary antibody used at a dilution of 1:100. 
Immediately afterwards the sections were incubated 
with EnVision Systems (Dako Deutschland GmbH, 
Hamburg, Germany) at room temperature (15 min). The 
peroxidase reaction was visualized with diamino-
benzidine and H2O2. The omission of the primary 
antibody in some sections was used as control of the 
immunostaining; no signal was obtained with the only 
incubation being the secondary antibody.   
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Statistical data analysis was conducted by the use of the 
statistic software GraphPath Prism 6.01. The Mann-
Whitney test was used for comparison between two 
groups. For comparison between more than two groups, 
we used the One-way ANOVA test followed by Tukey 
post hoc analysis. All correlation studies were computed 
by using the non-parametric Spearman correlation test 
(two-tailed) in a confidence interval of 95%. P-values 
below 0.05 are considered as significant. Optimal cut off 




Aβ, Amyloid beta; AUC, relative area under the curve; 
CJD, Creutzfeldt-Jakob disease; sCJD, sporadic CJD; 
CSF, cerebrospinal fluid; MDH1, mitochondrial malate 
dehydrogenase 1; NSE,  neuron specific enolase; PrPC, 
cellular prion protein; PrPSc, scrapie prion protein; 
ROC, receiver operating characteristic; rpm, revolutions 
per minute; RT-QuIC, real-time quaking-induced 
conversion; SEM, standard error of the mean; S-100B, 
S-100 calcium-binding protein B; TSE, transmissible 
spongiforme encephalopathies, total tau, tau.  
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